-
公开(公告)号:US09238080B2
公开(公告)日:2016-01-19
申请号:US13068808
申请日:2011-05-20
申请人: Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre , Shaun M. Lippow
发明人: Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre , Shaun M. Lippow
CPC分类号: C07K16/44 , A61K38/00 , A61K45/06 , A61K47/66 , A61K47/6811 , A61K47/6891 , B82Y5/00 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/65 , C07K16/46 , C07K2317/31 , C07K2317/76 , C07K2319/00 , C07K2319/80 , C12N15/62
摘要: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
摘要翻译: 提供了具有治疗用途的双特异性融合蛋白,以及包含这种融合蛋白的药物组合物,以及使用这种融合蛋白修复或再生受损或患病组织的方法。 双特异性融合蛋白通常包含:(a)靶向靶分子结合的靶向多肽结构域; 和(b)可检测地调节组织再生的活化剂结构域。
-
公开(公告)号:US08691771B2
公开(公告)日:2014-04-08
申请号:US13112907
申请日:2011-05-20
申请人: Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre
发明人: Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre
IPC分类号: A61K38/16
CPC分类号: C07K16/44 , A61K38/00 , A61K45/06 , A61K47/66 , A61K47/6811 , A61K47/6891 , B82Y5/00 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/65 , C07K16/46 , C07K2317/31 , C07K2317/76 , C07K2319/00 , C07K2319/80 , C12N15/62
摘要: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
摘要翻译: 提供了具有治疗用途的双特异性融合蛋白,以及包含这种融合蛋白的药物组合物,以及使用这种融合蛋白修复受损组织的方法。 双特异性融合蛋白通常包含:(a)与缺血相关分子结合的靶向多肽结构域; 和(b)可检测地调节细胞网络的活性的激活子结构域。
-
公开(公告)号:US20110293579A1
公开(公告)日:2011-12-01
申请号:US13068808
申请日:2011-05-20
申请人: Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre , Shaun Lippow
发明人: Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre , Shaun Lippow
CPC分类号: C07K16/44 , A61K38/00 , A61K45/06 , A61K47/66 , A61K47/6811 , A61K47/6891 , B82Y5/00 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/65 , C07K16/46 , C07K2317/31 , C07K2317/76 , C07K2319/00 , C07K2319/80 , C12N15/62
摘要: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
摘要翻译: 提供了具有治疗用途的双特异性融合蛋白,以及包含这种融合蛋白的药物组合物,以及使用这种融合蛋白修复或再生受损或患病组织的方法。 双特异性融合蛋白通常包含:(a)靶向靶分子结合的靶向多肽结构域; 和(b)可检测地调节组织再生的活化剂结构域。
-
-